ACE and chronic kidney disease: Treatment with either an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker was more common in CKD participants (47.2% vs 21.5, P < .001) while use of non-steroidal anti-inflammatory drugs was significantly common in those with CKD than without CKD (9.3% vs 6.1%, P < .005) Table 4.